Sak A, Stueben G, Groneberg M, Böcker W, Stuschke M
Department of Radiotherapy, University Hospital Essen, 45122 Essen, Germany.
Br J Cancer. 2005 Mar 28;92(6):1089-97. doi: 10.1038/sj.bjc.6602457.
The aim of the present work was to study the role of Rad51-dependent homologous recombination in the radiation response of non-small-cell lung cancer (NSCLC) cell lines. A dose- and time-dependent increase in the formation of Rad51 and gamma-H2AX foci with a maximum at about 4 and 1 h after irradiation, followed by a decrease, has been found. The relative fraction of cells with persisting Rad51 foci was 20-30% in radioresistant and 60-80% in radiosensitive cell lines. In comparison, a higher fraction of residual Dsb was evident in cell lines with nonfunctional p53. Transfection with As-Rad51 significantly downregulates radiation-induced formation of Rad51 foci and increases apoptosis, but did not influence the rejoining of DNA double-strand breaks. Interestingly, wortmannin, a well-known inhibitor of nonhomologous end-joining, also inhibits Rad51 foci formation. In general, there was no correlation between the clonogenic survival at 2 Gy and the percentage of initial Rad51 or gamma-H2AX foci after ionising radiation (IR). The most reliable predictive factor for radiosensitivity of NSCLC cell lines was the relative fraction of Rad51 foci remaining at 24 h after IR. Although most of the Rad51 foci are co-localised with gamma-H2AX foci, no correlation of the relative fraction of persisting gamma-H2AX foci and SF2 is evident.
本研究的目的是探讨Rad51依赖的同源重组在非小细胞肺癌(NSCLC)细胞系辐射反应中的作用。研究发现,Rad51和γ-H2AX焦点的形成呈剂量和时间依赖性增加,在照射后约4小时和1小时达到最大值,随后下降。在放射抗性细胞系中,持续存在Rad51焦点的细胞相对比例为20%-30%,在放射敏感细胞系中为60%-80%。相比之下,p53功能缺失的细胞系中残留双链断裂的比例更高。用反义Rad51转染可显著下调辐射诱导的Rad51焦点形成并增加细胞凋亡,但不影响DNA双链断裂的重新连接。有趣的是,渥曼青霉素是一种著名的非同源末端连接抑制剂,它也能抑制Rad51焦点的形成。总体而言,2 Gy时的克隆存活与电离辐射(IR)后初始Rad51或γ-H2AX焦点的百分比之间没有相关性。NSCLC细胞系放射敏感性最可靠的预测因子是IR后24小时仍存在的Rad51焦点的相对比例。尽管大多数Rad51焦点与γ-H2AX焦点共定位,但持续存在的γ-H2AX焦点的相对比例与SF2之间没有明显相关性。
Int J Radiat Biol. 2013-5-15
Mol Cancer Ther. 2018-11-26
J Thorac Oncol. 2013-3
Onco Targets Ther. 2021-8-4
Mol Cancer Res. 2003-10